Overview of progress in FY18
As a brief recap, major achievements through FY18 included:
1. An investment in our peptide libraries to triple their diversity and therefore richness as a source of drug candidates;
2. Adoption of high throughput screening capability in order to sample the richness of these libraries in identifying our ‘second generation’ of CPPs; and
3. Validation of our CPP platform in vivo (in animals) using our ‘first generation’ of CPPs with the Cre recombinase cargo to demonstrate effective drug delivery into a range of different tissue types.
To view Report please download PDF attached:
Download this document
